{"id":"cc-122","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CC-122 works by inhibiting the immunoproteasome, which is involved in the processing and presentation of antigens to the immune system. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.","oneSentence":"CC-122 is a selective inhibitor of the immunoproteasome.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:49:47.532Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05688475","phase":"PHASE1","title":"A Rollover Study of CC-122","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-04-11","conditions":"Non-Hodgkin Lymphoma","enrollment":12},{"nctId":"NCT02509039","phase":"PHASE1","title":"A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Celgene","startDate":"2015-09-02","conditions":"Lymphoma, Non-Hodgkin","enrollment":15},{"nctId":"NCT03310619","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-20","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular","enrollment":62},{"nctId":"NCT02031419","phase":"PHASE1","title":"Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma","status":"TERMINATED","sponsor":"Celgene","startDate":"2013-12-18","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":174},{"nctId":"NCT01421524","phase":"PHASE1","title":"Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-09-12","conditions":"Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier","enrollment":271},{"nctId":"NCT02417285","phase":"PHASE1","title":"A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-05-22","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin","enrollment":75},{"nctId":"NCT03834623","phase":"PHASE2","title":"Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-05-14","conditions":"Melanoma","enrollment":23},{"nctId":"NCT02406742","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-07-27","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":47},{"nctId":"NCT02859324","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-09-20","conditions":"Carcinoma, Hepatocellular","enrollment":21},{"nctId":"NCT03283202","phase":"PHASE1","title":"Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-10-04","conditions":"Diffuse B-Cell Lymphoma","enrollment":35},{"nctId":"NCT02234999","phase":"PHASE1","title":"Radiolabeled Study of CC-122 in Healthy Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-09-23","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT02049528","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-01-16","conditions":"Clinical Pharmacology, Healthy Male Volunteer Study","enrollment":18},{"nctId":"NCT03340662","phase":"PHASE1","title":"Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-11-09","conditions":"Healthy Volunteer","enrollment":81},{"nctId":"NCT03097016","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-03-30","conditions":"Renal Insufficiency","enrollment":48},{"nctId":"NCT02323906","phase":"PHASE1","title":"Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2015-01-16","conditions":"Carcinoma, Hepatocellular","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avadomide","BMS-986381"],"phase":"phase_2","status":"active","brandName":"CC-122","genericName":"CC-122","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-122 is a selective inhibitor of the immunoproteasome. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":13,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}